Chemically activated nanocapsid functionalized for cancer targeting
US10053494B2 · kind B2 · utility
Assignee
Inventors
Key dates
| Filing date | May 18, 2015 |
| Grant date | Aug 21, 2018 |
| Priority date | — |
| Expiry date | May 18, 2035 |
Classification
- Technology area (CPC G)Physics
- CPC primaryG01N2333/08
- WIPO fieldPharmaceuticals
- WIPO sectorChemistry
Abstract
Modified capsid proteins containing at least a portion of hepatitis E virus (HEV) open reading frame 2 (ORF2) having one or more cysteine residues in a surface variable loop or the C-terminus of HEV ORF2, or a portion thereof, are provided. The modified capsid proteins can be used to form hepatitis E virus (HEV) virus like particles (VLPs) having cysteine functional groups exposed on the outer-surface. The exposed cysteine functional groups can be modified via their thiol reactive group. For example, a bioactive agent, such as a cell-targeting ligand, can be conjugated to the one or more cysteines for targeted delivery of chemically activated nanocapsids.
Source: USPTO / EPO open patent data. Objective bibliographic and citation counts.